3例抗精神病药物所致迟发性运动障碍患者的护理被引量：2

下载PDF

导出

摘要总结3例抗精神病药物所致迟发型运动障碍患者的护理经验,包括:避免出现噎食、摔伤等危险事件;对于2例症状较轻者,进行功能训练,避免出现废用综合征,鼓励患者完成自我照顾的行为;对于1例病情严重者,加强营养支持;做好患者及家属的心理护理,让患者建立治疗的信心,降低家属的期望值,同时鼓励家属参与患者长期的康复治疗中,降低其照顾者无力感。经治疗护理,本组2例患者(病例1、病例2)未发生废用综合征,有治疗的信心,能带着症状完成生活自理;病例3由于长期的不自主运动,耗竭而死亡。

作者秦冬林闫宏伟柳学华

机构地区北京大学第六医院卫计委精神卫生学重点实验室临床心理科

出处《护理学报》 2014年第3期68-70,共3页 Journal of Nursing（China）

关键词迟发性运动障碍精神分裂症抗精神病药物药物不良反应护理

分类号 R473.74 [医药卫生—护理学]

引文网络
相关文献

参考文献9

1沈渔邨.精神病学[M]北京:人民卫生出版社,1995929.
2管晓波,陆峥,王宇卉.迟发性运动障碍的诊疗进展[J].世界临床药物,2012,33(10):595-598. 被引量：8
3Albayrak Y,Ekinci O. Duloxetine-Associated Tardive Dyskinesia Resolved with Fluvoxamine:A Case Report[J].{H}Clinical Psychopharmacology,2012,(05):723-724.
4Lally J,Byrne F,Walsh E. A Case of Paliperidone-Palmi-tate-Induced Tardive Dyskinesia[J].{H}General Hospital Psychiatry,2013,(02):213-217.
5Sarró S,Pomarol-Clotet. Structural Brain Changes Associated with Tardive Dyskinesia in Schizophrenia[J].{H}British Journal of Phychiatry,2012,(04):356-358.
6Seeman P,Tinazzi M. Loss of Dopamine Neuron Terminals in Antipsychotic-Treated Schizophrenia,Relation to Tardive Dyskinesia[J].{H}Progress in neuro-Psychopharmacology & Biological Psychiatry,2013,(05):44.
7Stanly N,Groff M G. Movement Disorders Induced by An-tipsychotic Drugs:Implications of the CATIE Schizophrenia Trial[J].{H}NEUROLOGIC CLINICS,2011,(01):127.
8张明园.精神科评定量表手册[M]{H}长沙:湖南科学技术出版社,1998205-207.
9Smith J M. Changes in Prevalence,Severity and Recovery in Tardive Dyskinesia with Age[J].{H}Archives of General Psychiatry,2000,(01):1368-1373.

二级参考文献31

1Saifee TA, Edwards MJ. Tardive movement disorders: a practical approach [J]. Pract Neurol, 2011, 11 (6) : 341-348.
2Margoiese HC, Chouinard FG, Koiivakis TT, et al. Tardive dyskinesia in the era of typicai and atypicai antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia[J]. Can J Psychiatry, 2005, 50 (11) : 695-703.
3Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics [J]. Curr Opin Psychiatry, 2008, 21 (2): 151-156.
4Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence [J].J Clin Psychiatry, 2004, 65 (Suppl 9) : S16-s20.
5Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia[J]. Aliment Pharmacol Ther, 2010, 31 (1) : 11-19.
6Caroff SN, Hurford I, Lybrand J, et al. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial[J]. Neurol Clin, 2011, 29 (1): 127-148.
7Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis [J]. Mov Disord, 2009, 24 (16) : 2309-2315.
8Margolese HC, Chouinard G, Kolivakis TT, et al. Tardiv1 dyskinesia in the era of typical and atypical antipsychotic Part 1 : pathophysiology and mechanisms of induction [J].Can J Psychiatry, 2005, 50 (9) : 541-547.
9Thelma B, Srivastava V, Tiwari AK. Genetic underpinnings tardive dyskinesia: passing the baton to pharmacogenetics[J].Pharmacogennmics, 2008, 9 (9) : 1285-1306.
10Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [J]. Arch Gen Psychiatry, 1982, 39 (4) : 486-487.